Abstract
Mortality data were retrieved from the Swedish death registry for the years 1970-2006. This report presents updated information on mortality from Alzheimers disease (AD) through the year 2006, as well as a statistical model of AD mortality with predictive value. This model was developed based on a mortality risk function acting after a specific time point, either step-wise on the whole population or on an increasing part of it. Data collected in recent years indicate that mortality is increasing continuously amongst the oldest patients, while younger age-groups show more stable mortality rates. After fitting the statistical model to age-standardized mortality data it also gave age-specific rates that fit well with reported data without further adjustments in model parameters. The data and the corresponding model for AD mortality suggest that the ability of the body to protect itself from AD-related neurological damage has in general became increasingly impaired since about 1985. This impairment has mainly affected people 65 years of age and older since 1985; the model predicts that in 2020, the age-standardized mortality in Sweden will be 13/100,000 person-years. The author concludes that the increasing mortality is real and not only a result of increasing use of the death classification code for AD.
Keywords: Alzheimer's disease, mortality, mobile phone, blood-brain barrier
Current Alzheimer Research
Title: Is Increased Mortality from Alzheimers Disease in Sweden a Reflection of Better Diagnostics?
Volume: 6 Issue: 6
Author(s): Orjan Hallberg
Affiliation:
Keywords: Alzheimer's disease, mortality, mobile phone, blood-brain barrier
Abstract: Mortality data were retrieved from the Swedish death registry for the years 1970-2006. This report presents updated information on mortality from Alzheimers disease (AD) through the year 2006, as well as a statistical model of AD mortality with predictive value. This model was developed based on a mortality risk function acting after a specific time point, either step-wise on the whole population or on an increasing part of it. Data collected in recent years indicate that mortality is increasing continuously amongst the oldest patients, while younger age-groups show more stable mortality rates. After fitting the statistical model to age-standardized mortality data it also gave age-specific rates that fit well with reported data without further adjustments in model parameters. The data and the corresponding model for AD mortality suggest that the ability of the body to protect itself from AD-related neurological damage has in general became increasingly impaired since about 1985. This impairment has mainly affected people 65 years of age and older since 1985; the model predicts that in 2020, the age-standardized mortality in Sweden will be 13/100,000 person-years. The author concludes that the increasing mortality is real and not only a result of increasing use of the death classification code for AD.
Export Options
About this article
Cite this article as:
Hallberg Orjan, Is Increased Mortality from Alzheimers Disease in Sweden a Reflection of Better Diagnostics?, Current Alzheimer Research 2009; 6 (6) . https://dx.doi.org/10.2174/156720509790147098
DOI https://dx.doi.org/10.2174/156720509790147098 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors as Anti-Angiogenic Agents in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Recombinant Murine Polyoma Virus-like-particles Induce Protective Antitumour Immunity
Letters in Drug Design & Discovery Structure Based Drug Design and Molecular Docking Studies of Anticancer Molecules Paclitaxel, Etoposide and Topotecan using Novel Ligands
Current Drug Discovery Technologies The Effect of Chemotherapy/Radiotherapy on Cancerous Pattern Recognition by NK Cells
Current Medicinal Chemistry Stathmin, Interacting with Nf-κB, Promotes Tumor Growth and Predicts Poor Prognosis of Pancreatic Cancer
Current Molecular Medicine Regulation of Hypoxia-inducible Factor-1α and Vascular Endothelial Growth Factor Signaling by Plant Flavonoids
Mini-Reviews in Medicinal Chemistry A Review on Chemical Profile of Coumarins and their Therapeutic Role in the Treatment of Cancer
Current Drug Delivery Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes
Current Genomics Targeting Aldose Reductase for the Treatment of Cancer
Current Cancer Drug Targets c-Myc and Downstream Targets in the Pathogenesis and Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Nanotechnology-based Herbal Formulations: A Survey of Recent Patents, Advancements, and Transformative Headways
Recent Patents on Nanotechnology Targeting MDM2 and MDMX in Retinoblastoma
Current Cancer Drug Targets Apis mellifera Proteomics: Where Will the Future Bee?
Current Proteomics Targeting of Hsp32 in Solid Tumors and Leukemias: A Novel Approach to Optimize Anticancer Therapy (Supplementry Material)
Current Cancer Drug Targets A Simplified Protocol Employing Elacridar in Rodents: A Screening Model in Drug Discovery to Assess P-gp Mediated Efflux at the Blood Brain Barrier
Drug Metabolism Letters Therapeutic Potential, Challenges and Future Perspective of Cancer Stem Cells in Translational Oncology: A Critical Review
Current Stem Cell Research & Therapy Synthesis, Immunomodulation and Cytotoxic Effects of Vanadium (IV) Complexes
Medicinal Chemistry The Therapeutic Potential of RNA Interference: Novel Approaches for Cancer Treatment
Current Pharmaceutical Biotechnology Disintegrin Tablysin-15 Suppresses Cancer Hallmarks in Melanoma Cells by Blocking FAK/Akt/ERK and NF-κB Signaling
Current Cancer Drug Targets An Overview of Piperazine Scaffold as Promising Nucleus for Different Therapeutic Targets
Current Pharmaceutical Design